Gaurav Shah, Rocket Pharmaceuticals CEO
Touting 100% OS rate in pivotal rare disease trial, Rocket Pharma ready to head to FDA
In drug development, you don’t throw around the word “cure” lightly. But Rocket Pharmaceuticals’ latest cut of gene therapy data has at least one analyst …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
